Creative Planning’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$21.5M Buy
117,236
+27,234
+30% +$5.02M 0.01% 412
2025
Q4
$15.8M Buy
90,002
+21,419
+31% +$3.5M 0.01% 460
2025
Q3
$9.61M Buy
68,583
+13,176
+24% +$1.78M 0.01% 580
2025
Q2
$6.96M Buy
55,407
+28,835
+109% +$3.59M 0.01% 644
2025
Q1
$3.64M Buy
26,572
+2,026
+8% +$290K ﹤0.01% 836
2024
Q4
$3.75M Buy
24,546
+10,772
+78% +$1.82M ﹤0.01% 785
2024
Q3
$2.67M Sell
13,774
-4,500
-25% -$941K ﹤0.01% 918
2024
Q2
$4.24M Buy
18,274
+4,473
+32% +$972K ﹤0.01% 684
2024
Q1
$2.98M Buy
13,801
+1,298
+10% +$304K ﹤0.01% 805
2023
Q4
$3.24M Sell
12,503
-767
-6% -$188K 0.01% 711
2023
Q3
$3.41M Sell
13,270
-1,604
-11% -$429K ﹤0.01% 647
2023
Q2
$4.24M Buy
14,874
+1,261
+9% +$375K 0.01% 568
2023
Q1
$3.78M Buy
13,613
+108
+0.8% +$29.9K 0.01% 575
2022
Q4
$3.74M Buy
13,505
+1,893
+16% +$535K 0.01% 548
2022
Q3
$3.1M Buy
11,612
+425
+4% +$90.3K 0.01% 555
2022
Q2
$2.28M Sell
11,187
-1,504
-12% -$307K ﹤0.01% 675
2022
Q1
$2.67M Sell
12,691
-297
-2% -$64.6K ﹤0.01% 633
2021
Q4
$3.12M Sell
12,988
-661
-5% -$170K 0.01% 557
2021
Q3
$3.86M Buy
13,649
+656
+5% +$215K 0.01% 487
2021
Q2
$4.5M Sell
12,993
-12,580
-49% -$3.81M 0.01% 437
2021
Q1
$7.15M Sell
25,573
-177
-0.7% -$47.7K 0.01% 333
2020
Q4
$6.3M Sell
25,750
-583
-2% -$150K 0.01% 332
2020
Q3
$7.47M Buy
26,333
+645
+3% +$180K 0.02% 260
2020
Q2
$6.87M Sell
25,688
-582
-2% -$175K 0.02% 239
2020
Q1
$8.31M Buy
26,270
+212
+0.8% +$64.3K 0.03% 185
2019
Q4
$7.73M Sell
26,058
-85
-0.3% -$23.6K 0.02% 233
2019
Q3
$6.09M Sell
26,143
-1,372
-5% -$319K 0.02% 252
2019
Q2
$6.43M Sell
27,515
-1,368
-5% -$316K 0.02% 243
2019
Q1
$6.83M Buy
28,883
+1,867
+7% +$588K 0.02% 218
2018
Q4
$8.13M Sell
27,016
-1,596
-6% -$509K 0.03% 173
2018
Q3
$10.1M Buy
28,612
+834
+3% +$287K 0.04% 164
2018
Q2
$8.06M Sell
27,778
-155
-0.6% -$43.6K 0.03% 179
2018
Q1
$7.65M Sell
27,933
-348
-1% -$108K 0.03% 180
2017
Q4
$9.01M Buy
28,281
+2,013
+8% +$646K 0.04% 154
2017
Q3
$8.22M Sell
26,268
-19,510
-43% -$5.78M 0.04% 159
2017
Q2
$12.4M Sell
45,778
-2,713
-6% -$717K 0.06% 117
2017
Q1
$13.3M Buy
48,491
+4,861
+11% +$1.37M 0.07% 105
2016
Q4
$12.4M Buy
43,630
+6,640
+18% +$1.97M 0.08% 104
2016
Q3
$11.6M Sell
36,990
-478
-1% -$142K 0.07% 110
2016
Q2
$9.06M Buy
37,468
+5,545
+17% +$1.46M 0.07% 112
2016
Q1
$8.31M Buy
31,923
+9,053
+40% +$2.39M 0.06% 112
2015
Q4
$7.01M Sell
22,870
-72
-0.3% -$20.7K 0.06% 127
2015
Q3
$6.7M Buy
+22,942
New +$7.58M 0.06% 130
2015
Q2
Sell
-6,316
Closed -$2.67M 1298
2015
Q1
$2.67M Buy
6,316
+1,762
+39% +$694K 0.03% 231
2014
Q4
$1.55M Buy
4,554
+284
+7% +$91.9K 0.02% 334
2014
Q3
$1.41M Buy
4,270
+491
+13% +$162K 0.02% 313
2014
Q2
$1.19M Buy
3,779
+344
+10% +$104K 0.02% 340
2014
Q1
$1.05M Buy
3,435
+908
+36% +$288K 0.02% 358
2013
Q4
$706K Sell
2,527
-97
-4% -$25.1K 0.01% 409
2013
Q3
$632K Sell
2,624
-461
-15% -$103K 0.01% 378
2013
Q2
$664K Buy
+3,085
New +$659K 0.02% 331

Other funds holding BIIB

Creative Planning's BIIB Position: Q1 2026 in Review

Creative Planning increased its Biogen (BIIB) stake by 30% in Q1 2026, buying an estimated $5.02M and bringing the position to 117,236 shares worth $21.5M. The position accounts for 0.01% of the portfolio, ranked #412.

Creative Planning first reported a position in BIIB in Q2 2013 and has held it in 51 quarters since. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Creative Planning held 117,236 shares of Biogen worth $21.5M as of Q1 2026.
  • Creative Planning bought 27,234 Biogen shares in Q1 2026, an estimated $5.02M.
  • Biogen made up 0.01% of Creative Planning's portfolio in Q1 2026, its #412 holding.
  • Creative Planning first reported a position in Biogen in Q2 2013 and has held it in 51 quarters since.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.